Hostname: page-component-7c8c6479df-27gpq Total loading time: 0 Render date: 2024-03-28T21:18:26.648Z Has data issue: false hasContentIssue false

Progressively worsening hypertrophic cardiomyopathy in a child with newly diagnosed Costello syndrome while receiving growth hormone therapy

Published online by Cambridge University Press:  22 March 2010

Daisuke Kobayashi*
Affiliation:
Division of Pediatric Cardiology, Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America
Amanda L. Cook
Affiliation:
Division of Pediatric Cardiology, Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America
Derek A. Williams
Affiliation:
Division of Pediatric Cardiology, Department of Pediatrics, Wake Forest University School of Medicine, Winston-Salem, North Carolina, United States of America
*
Correspondence to: Dr D. Kobayashi, MD, Division of Pediatric Cardiology, Department of Pediatrics, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC 27157, United States of America. Tel: +336 716 2694; Fax: +336 716 7100; E-mail: dkobayas@wfubmc.edu

Abstract

We describe a 6-year-old boy with newly diagnosed Costello syndrome after the diagnosis of severe hypertrophic cardiomyopathy. His neonatal asymmetric septal cardiomyopathy resolved by 9 months of age but reappeared at 6 years of age. This report highlights two important concepts: the association of genetic syndromes with hypertrophic cardiomyopathy and the possibility of worsening severity of hypertrophic cardiomyopathy linked to growth hormone therapy.

Type
Brief Reports
Copyright
Copyright © Cambridge University Press 2010

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1. van Eeghen, AM, van Gelderen, I, Hennekam, RC. Costello syndrome: report and review. Am J Med Genet 1999; 82: 187193.Google Scholar
2. Kerr, B, Einaudi, MA, Clayton, P, et al. Is growth hormone treatment beneficial or harmful in Costello syndrome? J Med Genet 2003; 40: e74e76.Google Scholar
3. Aoki, Y, Niihori, T, Kawame, H, et al. Germline mutations in HRAS proto-oncogene cause Costello syndrome. Nat Genet 2005; 37: 10381040.Google Scholar
4. Giehl, K. Oncogenic Ras in tumor progression and metastasis. Biol Chem 2005; 386: 193205.Google Scholar
5. Quezada, E, Gripp, KW. Costello syndrome and related disorders. Curr Opi Pediatr 2007; 19: 636644.Google Scholar
6. Digilio, MC, Sarkozy, A, Capolino, R, et al. Costello syndrome: Clinical diagnosis in the first year of life. Eur J Pedatr 2008; 167: 621628.Google Scholar
7. Lin, AE, Grossfeld, PD, Hamilton, RM, et al. Further delineation of cardiac abnormalities in Costello syndrome. Am J Med Genet 2002; 111: 115129.Google Scholar
8. Rauen, KA, Hefner, E, Carrillo, K, et al. Molecular aspects, clinical aspects and possible treatment modalities for Costello syndrome: proceedings from the 1st International Costello Syndrome Research Symposium 2007. Am J Med Genet 2008; 146A: 12051217.Google Scholar